184 related articles for article (PubMed ID: 10072628)
1. Expression of bcl-2, p53 oncoprotein, and proliferating cell nuclear antigen in renal cell carcinoma.
Sejima T; Miyagawa I
Eur Urol; 1999; 35(3):242-8. PubMed ID: 10072628
[TBL] [Abstract][Full Text] [Related]
2. The relationship of expression of bcl-2, p53, and proliferating cell nuclear antigen (PCNA) to cell proliferation and apoptosis in renal cell carcinoma.
Zhu Z; Xing S; Cheng P; Li G; Yang Y; Zeng F; Lu G
J Huazhong Univ Sci Technolog Med Sci; 2004; 24(4):354-7. PubMed ID: 15587397
[TBL] [Abstract][Full Text] [Related]
3. Co-expression of p53 and bcl-2 may correlate to the presence of epstein-barr virus genome and the expression of proliferating cell nuclear antigen in nasopharyngeal carcinoma.
Niemhom S; Kitazawa S; Murao S; Kunachak S; Maeda S
Cancer Lett; 2000 Nov; 160(2):199-208. PubMed ID: 11053650
[TBL] [Abstract][Full Text] [Related]
4. Bcl-2 and proliferating cell nuclear antigen (PCNA) expression correlates with subsequent local recurrence in nasopharyngeal carcinomas.
Tsai ST; Jin YT; Leung HW; Wang ST; Tsao CJ; Su IJ
Anticancer Res; 1998; 18(4B):2849-54. PubMed ID: 9713473
[TBL] [Abstract][Full Text] [Related]
5. Thymidylate synthase expression, p53, bcl-2, Ki-67 and p27 in colorectal cancer: relationships with tumor recurrence and survival.
Rosati G; Chiacchio R; Reggiardo G; De Sanctis D; Manzione L
Tumour Biol; 2004; 25(5-6):258-63. PubMed ID: 15627889
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical study of bcl-2, p53 and Ki-67 expressions in collecting duct carcinoma of the kidney. Five cases and review of the literature on bcl-2, p53 and Ki-67 expressions in renal cell carcinoma and transitional cell carcinoma.
Suzuki K; Tokue A
Urol Int; 2002; 69(1):57-62. PubMed ID: 12119441
[TBL] [Abstract][Full Text] [Related]
7. Expression of cyclin D1, Ki-67 and PCNA in non-small cell lung cancer: prognostic significance and comparison with p53 and bcl-2.
Nguyen VN; Mirejovský P; Mirejovský T; Melínová L; Mandys V
Acta Histochem; 2000 Aug; 102(3):323-38. PubMed ID: 10990069
[TBL] [Abstract][Full Text] [Related]
8. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer.
Korkolopoulou P; Christodoulou P; Kapralos P; Exarchakos M; Bisbiroula A; Hadjiyannakis M; Georgountzos C; Thomas-Tsagli E
Pathol Res Pract; 1997; 193(11-12):767-75. PubMed ID: 9521509
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical detection of proliferating cell nuclear antigen and p53 expression in carcinoma of the extrahepatic bile duct.
Suto T; Sugai T; Nakamura S; Uesugi N; Sasaki R; Kanno S; Saito K
Oncology; 1997; 54(5):407-13. PubMed ID: 9260603
[TBL] [Abstract][Full Text] [Related]
10. Expression of the antiapoptotic protein bcl-2 is not dependent on the tumor suppressor p53 protein in Indian breast carcinoma.
Kesari AL; Chellam VG; Madhavan J; Nair PP; Nair MK; Pillai MR
Pathobiology; 1997; 65(2):108-12. PubMed ID: 9253035
[TBL] [Abstract][Full Text] [Related]
11. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2.
Haitel A; Posch B; El-Baz M; Mokhtar AA; Susani M; Ghoneim MA; Marberger M
J Urol; 2001 May; 165(5):1481-7. PubMed ID: 11342901
[TBL] [Abstract][Full Text] [Related]
12. Conventional (clear cell) renal carcinoma metastases have greater bcl-2 expression than high-risk primary tumors.
Lee CT; Genega EM; Hutchinson B; Fearn PA; Kattan MW; Russo P; Reuter VE
Urol Oncol; 2003; 21(3):179-84. PubMed ID: 12810203
[TBL] [Abstract][Full Text] [Related]
13. Can p53 nuclear over-expression, Bcl-2 accumulation and PCNA status be of prognostic significance in high-risk superficial and invasive bladder tumours?
Plastiras D; Moutzouris G; Barbatis C; Presvelos V; Petrakos M; Theodorou C
Eur J Surg Oncol; 1999 Feb; 25(1):61-5. PubMed ID: 10188857
[TBL] [Abstract][Full Text] [Related]
14. Tumour suppressor protein (p53), apoptosis inhibiting protein (Bcl-2) and proliferating cell nuclear antigen (PCNA) expressions in a rat pancreatic tumour model.
Mäkinen K; Loimas S; Hakala T; Eskelinen M
Anticancer Res; 2007; 27(1A):23-6. PubMed ID: 17352211
[TBL] [Abstract][Full Text] [Related]
15. Expression of p53 and bcl-2 in primary locally confined renal cell carcinomas: no evidence for prognostic significance.
Hofmockel G; Wittmann A; Dammrich J; Bassukas ID
Anticancer Res; 1996; 16(6B):3807-11. PubMed ID: 9042262
[TBL] [Abstract][Full Text] [Related]
16. Y-box-binding protein-1 expression is not correlated with p53 expression but with proliferating cell nuclear antigen expression in non-small cell lung cancer.
Yoshimatsu T; Uramoto H; Oyama T; Yashima Y; Gu C; Morita M; Sugio K; Kohno K; Yasumoto K
Anticancer Res; 2005; 25(5):3437-43. PubMed ID: 16101161
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of ploidy and proliferation markers in renal cell carcinoma.
Tannapfel A; Hahn HA; Katalinic A; Fietkau RJ; Kühn R; Wittekind CW
Cancer; 1996 Jan; 77(1):164-71. PubMed ID: 8630925
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of immunohistochemically detectable p53 protein in renal cell carcinoma.
Shiina H; Igawa M; Urakami S; Shirakawa H; Ishibe T; Kawanishi M
Eur Urol; 1997; 31(1):73-80. PubMed ID: 9032539
[TBL] [Abstract][Full Text] [Related]
19. Expression of proliferating cell nuclear antigen and deoxyribonucleic acid value in renal cell carcinoma: correlation with different histopathological parameters and patient survival.
Shameem IA; Shimabukuro T; Wada T; Kurisu H; Naito K
Eur Urol; 1996; 29(1):78-84. PubMed ID: 8821696
[TBL] [Abstract][Full Text] [Related]
20. Expression of bcl-2 oncoprotein in transitional cell carcinoma of the upper urinary tract.
Nakanishi K; Tominaga S; Kawai T; Torikata C; Aurues T; Ikeda T
Virchows Arch; 1998 May; 432(5):445-50. PubMed ID: 9645444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
